Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: The EDITION 2 randomized 12-month trial including 6-month extension

Diabetes, Obesity and Metabolism

Volumn 17, Issue 12, 2015, Pages 1142-1149

  Yki Järvinen, Hannele ^a,b   Bergenstal, R M ^c   Bolli, G B ^d   Ziemen, M ^e   Wardecki, M ^f   Muehlen Bartmer, I ^e   Maroccia, M ^g   Riddle, M C ^h  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c INTERNATIONAL DIABETES CENTER   (United States)

^d UNIVERSITY OF PERUGIA   (Italy)

^e SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^f Sanofi Pasteur   (Poland)

^g Umanis   (France)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Basal insulin; Insulin glargine; Oral antihyperglycaemic drugs; Type 2 diabetes

Indexed keywords

BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; INSULIN DEGLUDEC; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT; HEMOGLOBIN A1C PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG CROSS REACTIVITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE REACTION; INSULIN PUMP; INTENTION TO TREAT ANALYSIS; MALE; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN; BLOOD; BLOOD GLUCOSE MONITORING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG FORMULATION; INCIDENCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT DROPOUT; RISK; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DRUG COMPOUNDING; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; INSULIN GLARGINE; INTENTION TO TREAT ANALYSIS; ISOPHANE INSULIN, HUMAN; MIDDLE AGED; PATIENT DROPOUTS; PATIENT SATISFACTION; RISK; WEIGHT GAIN;

EID: 84945442142     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12532     Document Type: Article

References (17)

1. -1. Diabetes Care 2015; 38: 637-643.
2. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract 2009; 63(Suppl. 164): 6-10.
3. Yki-Järvinen H, Bergenstal R, Ziemen M et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycaemia in a 6-month randomised controlled trial (EDITION 2). Diabetes Care 2014; 37: 3235-3243.
4. Bolli G, Riddle M, Bergenstal R et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in insulin naïve people with type 2 diabetes using anithyperglycemic drugs: glucose control and hypoglycemia in a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015; 17: 386-394.
5. Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014; 37: 2755-2762.
6. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
7. American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
8. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 1990; 7: 445-451.
9. Lewis KS, Bradley C, Knight G, Boulton AJ, Ward JD. A measure of treatment satisfaction designed specifically for people with insulin-dependent diabetes. Diabet Med 1988; 5: 235-242.
10. Garber AJ, King AB, Del Prato S et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
11. Zinman B, Philis-Tsimikas A, Cariou B et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
12. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013; 36: 2536-2542.
13. Riddle MC, Yki-Järvinen H, Bolli GB et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab 2015; 17: 835-842.
14. Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of EDITION 1, 2 and 3: glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes. Diabetes Obes Metab 2015; 17: 859-867.
15. Matsuhisa M, Koyama M, Cheng XN, Shimizu S, Hirose T, on behalf of the EDITION JP 1 study group. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM (EDITION JP 1). Diabetes 2014; 63(Suppl. 1A): LB22.
16. Home P, Bergenstal R, Riddle MC et al. Glycemic control and hypoglycemia with new insulin glargine 300 U/mL in people with T1DM (EDITION 4). Diabetes 2014; 63(Suppl. 1A): LB19.
17. Terauchi Y, Koyama M, Cheng XN, Shimizu S, Hirose T. Glycemic control and hypoglycemia in Japanese people with T2DM receiving new insulin glargin 300 U/mL in combination with OADs (EDITION JP 2). Diabetes 2014; 63: LB24.